Adian Ladron De Guevara

Experienced clinical research coordinator and registered nurse with a decade of dedicated service in the medical profession. Proficient in managing clinical trials, ensuring regulatory compliance, and facilitating seamless communication between stakeholders. Seeking to leverage my extensive background and passion for research in furthering the objectives of your esteemed team as a Clinical Research Coordinator.

• Registered Nurse in State of Florida
• Certification of Advanced Life Support
• Certification of CPR-BLS
• APEA Certification
• Certified Clinical Research Coordinator
• CITI Diploma
• ICH/GCP Certified
• IATA Certified
• Inform 4.6 Certified
• Data Labs Certified
• MediData Rave Certified

• Astrazeneca- A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator­ Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of XXXXXX Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma.

•  Pfizer-A Phase 2/3, Randomized, Double-Blind, Double-Dummy, Placebo Controlled Study To Evaluate The Safety And Efficacy Of 2 Regimens Of Orally Administered XXXXXXX In Preventing Symptomatic Sars-Cov-2 Infection In Adult Household Contacts Of An Individual With Symptomatic Covid-19.

•  Pfizer-An Interventional Efficacy And Safety, Phase 2/3, Double-Blind, 2-Arm Study To Investigate Orally Administered XXXXXXXX Compared With Placebo In Nonhospitalized Symptomatic Adult Participants With Covid-19 Who Are At Increased Risk Of Progressing To Severe Illness.

•  Pfizer-An Interventional Efficacy And Safety, Phase 2/3, Double-Blind, 2-Arm Study To Investigate Orally Administered XXXXXXX Compared With Placebo In Nonhospitalized Symptomatic Adult Participants With Covid-19 Who Are At Low Risk Of Progressing To Severe Illness.

• Pfizer- A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a XXXXXXXXX Vaccine in Healthy Infants.

• Kintor- A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of XXXXXX in Outpatients with Mild to Moderate COVID-19 Illness

•  Verona-A Phase III Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of XXXXXX over 24 Weeks (With a 48-Week Safety Subset) in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.

• Esperion-A Randomized, Double-Blind, Placebo-Controlled Study to Assess The Effects Of XXXXXXXX On The Occurrence Of Major Cardiovascular Events In Patients With, Or At High Risk For, Cardiovascular Disease Who Are Stalin Intolerant.

•  Biohaven-A Randomized, Double-Blind, Placebo-Controlled Trial of XXXXXXX in Obsessive Compulsive Disorder.

• Biohaven-A Multicenter, 48-week Open-Label Safety Study of XXXXXXX in Subjects with Obsessive Compulsive Disorder.

•  Regeneron- A Master Protocol Assessing The Safety, Tolerability, And Efficacy Of Anti-Spike (S) Sars-Cov-2 Monoclonal Antibodies For The Treatment Of Ambulatory Patients With Covid-19.

• Regeneron-A Phase 2 Study To Assess The Virologic Efficacy OfXXXX+XXXX Across Different Dose Regimens In Outpatients With Sars-Cov-2 Infection

•  Regeneron- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts oflndividuals Infected with SARS-CoV-2.

•  Celgene- Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of XXXXXXXXX As Induction Therapy For Moderately To Severely Active Crohn's Disease.

•  Celgene- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of XXXXXXX As Maintenance Therapy For Moderately To Severely Active Crohn's Disease.

• Celgene- A Phase 3, Multicenter, Open-Label Extension Study Of XXXXXXXX For Moderately To Severely Active Crohn's Disease.

•  Palladio-A Phase 3 Study of the Efficacy and Safety ofXXXXXXX in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1- year Double-blind, Placebo-controlled, Randomized Phase and a I-year Open-Label Phase: The XXXXX

•  Novo Nordisk- Efficacy and safety ofXXX versus XXXX ER 2.0mg once weekly as add- on to 1-2 oral antidiabetic drugs (OADs) in subjects with Type II Diabetes.

• AbbVie- A Randomized, Double- Blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy ofXXX with Moderate to Severe Endometriosis- Associated Pain.

•  Pfizer- Prospective Randomized Evaluation ofXXXXX Integrated Safety vs. Ibuprofen or Naproxen for Osteoarthritis or Rheumatoid Arthritis pain.

•  GlaxoSmithKline: Study to compare the effect ofXXX with Placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease.

•  AstraZeneca- A 26 week, randomized, double- blind, parallel- group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment.

•  Boeringer Ingelheim- 6 Months, Multicenter, Randomized, Open- label, Parallel Group Study Comparing the Efficacy and Safety of a New Formulation of XXX and XXX in Insulin- Naive Patients with Type II Diabetes Mellitus Not Adequately Controlled with Oral Antihyperglycemic Drugs with 6 months Comparative Extension Period.

• Baintree- A Safety and Efficacy Evaluation ofXXXX Laxative in Constipated Adults.

•  Sanofi- A randomized, open- label, parallel group real world pragmatic trial to assess the clinical and health outcomes to XXXX compared to commercially available basal insulin for initiation of therapy in naive patients with uncontrolled Type II Diabetes Mellitus.

•  Merck- A Phase III Randomized, Placebo- Controlled, Clinical Trial to Study the Safety and Efficacy in Adult Patients with Solid Tumor or Hematologic Malignancy.

•  Pfizer- Randomized, Double- Blind, Placebo- controlled, Parallel group Study to assess Cardiovascular Outcomes following treatment with XXXX (XX-XXXX/ XX-XXXX) in Subjects with Type II Diabetes Mellitus and Established Vascular Disease.

•  AstraZeneca- A randomized, Double- Blind, Double Dummy, Chronic Dosing (56 week) Placebo- controlled, Parallel Group, Multicenter, Phase III Study to Evaluate the Efficacy of 3 doses ofXXXX (XXX-XX) in patient with moderate to very severe Chronic Obstructive Pulmonary Disease.

• 2016 A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and

Tolerability of a Single Intravenous Dose ofX:XX in Subjects with Uncomplicated Influenza A Infection.

•  AstraZeneca- A multicenter, Double- Blind, Placebo- Controlled Parallel Group, Randomized, Phase III Study to Evaluate the Glycemic Efficacy and Renal Safety of X:XXX:XX in Patients with Type II Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) who have Inadequate Glycemic Control.

• AstraZeneca- A multi-center, randomized, double- blind, double- dummy, active controlled, 2- period cross- over study to assess the Efficacy, Safety and Tolerability of XXXXX-XXXI XXXX XXXXX compared to XXXX X:XXX/ XXXX in COPD patients with moderate to severe airflow limitation.

•  2017-AstraZeneca- A randomized, Double- Blind, Double Dummy, Chronic Dosing (56 week) Placebo- controlled, Parallel Group, Multicenter, Phase III Study to Evaluate the Efficacy of 3 doses of XXXXX (X:XX-XXX) in patient with moderate to very severe Chronic Obstructive Pulmonary Disease.

•  2017-AstraZeneca- A multicenter, Double- Blind, Placebo- Controlled Parallel Group, Randomized, Phase III Study to Evaluate the Glycemic Efficacy and Renal Safety of X:XXX:XX in Patients with Type II Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) who have Inadequate Glycemic Control.

•  2017-AstraZeneca- A multi-center, randomized, double- blind, double- dummy, active controlled, 2- period cross- over study to assess the Efficacy, Safety and Tolerability of X:XX-XXX/ XXXX-XXXX compared to XXXX XXXXX/XXXX in COPD patients with moderate to severe airflow limitation.

•  2017- PHASE 3, Randomized, open-label, active-controlled study evaluating the Efficacy and safety of oral XXXXX for the Correction of Anemia in subjects with non­ dialysis-dependent chronic kidney disease (NDD-CKD) (Pro2tect -correction)

•  2017- PHASE 3, Randomized, open-label, active-controlled study evaluating the Efficacy and Safety of oral XXXXX for the maintenance treatment of Anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (Pro2tect - Conversion)

• 2018- A randomized, double-blind, placebo-controlled study to assess the Effects bempedoic acid (XXX-XXX) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.

•  2018- A multicenter, double-blinded, randomized, placebo-controlled study to evaluate the Safety and Efficacy of oral XXX in chronic kidney disease patients with moderate­ ton severe pruritus.

•  2018- A Randomized, Double-blind, Placebo-controlled, parallel group clinical study to Assess the Safety and Efficacy of Three Doses ofX:XX XXX when administered intra orally Twice Daily in Patients with Oral Lichen Planus (OLP) using X:XX-CLO Patches.

• 2018- Induction study #1 -A Phase 3, multicenter, randomized, double-bind, placebo­ controlled study of oral XXXX as induction therapy for moderately to severely active Crohn's Disease.

• Phase III- Vaginal Dryness Study

• Phase III- Rosacea Study

• Phase II- Alzheimer Disease Study

• Phase II- Constipation

• Phase II- Travelers Diarrhea

• Phase III- Hypercholesterolemia Study

• 2024: South University - Master of Science (M.S.) - ARNP in Gerontology Candidate - 4.0 GPA - Deans List Each Semester
• 2023: West Coast University - Bachelor of Science (B.S.) in Nursing - 4.0 GPA - Graduated top 5% - Summa Cum Laude - Deans List Each Semester
• 2009: Medical Science Unuversity of Cuba - Doctorates in Med Surgical Specialty - 3.9 GPA - Graduated top 10% - Magna Cum Laude - Deans List Each Semester (2007-2009)